Approvals
Approvals
- Alert FDA Approves SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes
- FDA Warns About Amputation Risk With Canagliflozin
- New Continuous Glucose Monitor Software Improves Accuracy
- Alert Trametinib (Mekinist) Now Approved in EU for Melanoma
- Alert FDA Rejects Novo Nordisk's Insulin Degludec
- Alert FDA Approves Higher Dose of Hydromorphone
- Alert Carpuject Hydromorphone Prefilled Syringes Recalled
- Alert Immune Globulin Approved for Multifocal Motor Neuropathy
- Alert Pertuzumab Approved for HER2 Breast Cancer
- First Cord-Blood Transplant Therapy Approved by FDA
- Alert FDA Recalls Mizuho Surgical Tables
- FDA Approves Cetuximab for Metastatic Head and Neck Cancer
- Alert TNF Blockers and Cancer: FDA Requires Increased Surveillance
- Aneurysm Stent Okayed for Patients With Small Arteries
- FDA Okays Exparel for Postoperative Pain
- Europe Okays Pneumonia Vaccine for Adults 50 Years and Older
- Pemetrexed Approved in EU for NCSLC Continuation Maintenance
- European Nod for HG Nerve Stimulation in Sleep Apnea
- Alert FDA Provides Update on Drospirenone VTE Risk
- Alert Sepsis Drug Xigris Pulled From Worldwide Market